Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Millennium Begins Phase II RA Trial | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Millennium Begins Phase II RA Trial

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Millennium Pharmaceuticals, Inc. initiated a randomized, double-blind, placebo-controlled Phase II study of MLN3897 in patients with rheumatoid arthritis (RA). MLN3897, an oral, small molecule designed to block CCR1, is a chemokine receptor believed to play a role in inflammatory disorders including RA.

The study will assess the efficacy, safety and tolerability of MLN3897 in combination with methotrexate (MTX), a standard therapy for RA. As many as 186 patients with RA that have been taking MTX for at least six months prior to screening will be enrolled in the study. Patients will continue the MTX regimen and will receive MLN3897 or placebo. The primary endpoint of the study is ACR20 response rate, a standard clinical measurement for RA, which measures improvement in the number of tender and swollen joints and various levels of disease activity.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters